HDAC inhibitor tucidinostat and metronomic capecitabine plus endocrine therapy for patients with HR-positive HER2-negative advanced breast cancer after CDK4/6 inhibitors treatment: clinical findings and exploratory circulating tumor cell and ctDNA biomarker analyses of a multicenter, phase 2 study (SYSUCC-020 trial).

Signal Transduct Target Ther · 2026 · PMC13083885 · PMID 41986320

Europe PMC DOI

hedged sentence

0.0610

closest p · 1.2× alpha

0.0610

boldest claim

The sentences

approached significanceP = 0.061so close (0.05 < p ≤ 0.1)

In the univariate analysis, none of the factors reached statistical significance, although assignment to Cohort 2 approached significance (HR = 1.71, 95% CI 0.98–3.01, P = 0.061; Supplementary Table 3 ).

also in 8,237 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.